Search Results
KRYSTAL-1: adagrasib in NSCLC patients with CNS metastases
KRYSTAL-1: activity of adagrasib in KRASG12m NSCLC with untreated CNS metastases
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
KRYSTAL-1: adagrasib for KRAS-mutant NSCLC
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a ...
How will adagrasib fit into the treatment landscape of KRASG12-mutant NSCLC?
#ESMO21 Highlights on adagrasib in patients with KRASG12C-mutated CRC: The KRYSTAL-1 study
ASCO 2022: Dr. Alexander I. Spira on KRYSTAL-1 for Patients with Advanced/Metastatic NSCLC
Krystal 7 Study: Adagrasib +/- Pembrolizumab for KRAS G12C+ NSCLC -Targeted Therapies in Lung Cancer
Adagrasib for Previously Treated KRAS G12C+ NSCLC - ASCO Lung Review 2022
Adagrasib for KRAS G12C-mutated NSCLC
